N E W S B Y T E S
Next-generation sequencers market will reach $ 5.1 billion in 2033 , forecasts GlobalData
Novozymes completes merger with Chr . Hansen , new entity named as Novonesis
On December 12 , 2022 , Novozymes and Chr . Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies . All regulatory approvals and registrations are now in place and the proposed combination is successfully completed following the final registration with the Danish Business Authority .
Novonesis , the combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries . Ester Baiget , President and CEO of Novonesis , says : “ Novonesis combines our joint strengths and the wonders of biology , and we are set to lead a new era of biosolutions . We will innovate and develop transformative biosolutions that improve the way we all produce , consume and live .”
The next-generation sequencers market is poised to grow at a compound annual growth rate ( CAGR ) of 10.3 % from $ 1.9 billion in 2023 to $ 5.1 billion in 2033 , forecasts GlobalData , a leading data and analytics company . GlobalData ’ s latest report , “ Next Generation Sequencers Market Size by Segments , Share , Regulatory , Reimbursement , and Forecast to 2033 ,” visualizes quantitative market trends within IVD therapeutic area . Tina Deng , MSc , Principal Medical Devices Analyst at GlobalData , comments : “ The NGS market ’ s growth is fuelled by a combination of unaddressed clinical needs for more effective tools in predicting , diagnosing , treating , and monitoring diseases , along with the ongoing advancement of sequencing technologies for efficiency .”
08
BioVoiceNews | March / April 2024